Jubilant Pharmovas sterile injectable manufacturing arm commissions $132 million new line in U.S.

Jubilant Pharmova subsidiary and contract producer Jubilant HollisterStier LLC (JHS) has launched a $132 million new sterile fill and end line at its Spokane manufacturing facility in Washington, U.S..

It is the third such line of JHS, which specialises in sterile injectables and caters to main international innovator pharma corporations. The subsidiary is on monitor to double its whole sterile injectable manufacturing capability on the facility within the U.S., as soon as the upcoming fourth line is commissioned, the mum or dad firm mentioned on Friday (October 10, 2025).

“With third line operational and fourth on the horizon, we aren’t simply doubling our capability, we’re constructing a future that can create a whole bunch of latest jobs, strengthen the U.S. pharmaceutical provide chain and reaffirm our function as a trusted associate in delivering life-saving therapies to sufferers world wide,” CEO — CDMO Sterile Injectables Chris Preti mentioned in a launch.

Large innovator pharma corporations are on the lookout for prime quality, US manufacturing services within the wake of latest tariffs imposed by the U.S. authorities. In this backdrop, the corporate is witnessing a really robust traction in requests for proposals (RFPs) for the brand new line. “We anticipate to achieve the total utilisation for the brand new line within the subsequent three years,” he mentioned, in search of to reiterate how the growth displays the corporate’s deep-rooted dedication, to continued development, technological excellence and the neighborhood at Spokane.

The funding reinforces JHS’ management in home US pharmaceutical manufacturing. By increasing its infrastructure and growing onshore capability, the corporate is contributing to US nationwide well being safety and serving to to cut back reliance on offshore provide chains — delivering a extra resilient and agile pharmaceutical manufacturing ecosystem, Jubilant Pharmova (Jubilant Life Sciences) mentioned. The launch was marked by the profitable manufacturing of the inaugural batch, initiating income era from the brand new Line. The new line, outfitted with superior isolator know-how to ship enhanced sterility assurance, throughput and operational precision, is a part of a multi-phase growth technique. It brings a further 50% capability on the Spokane manufacturing facility.